MiR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN

International Journal of Molecular Medicine

Volumn 32, Issue 2, 2013, Pages 381-388

  Tang, Haosha ^a   Yao, Liangqing ^a   Tao, Xiang ^a   Yu, Yi ^a   Chen, Mo ^a   Zhang, Rong ^b   Xu, Congjian ^a,b  

^a FUDAN UNIVERSITY   (China)

^b Central Hospital of Fengxian District   (China)

Author keywords

MicroRNA 9; Ovarian cancer; Talin 1

Indexed keywords

FOCAL ADHESION KINASE; MICRORNA 9; PROTEIN; PROTEIN KINASE B; TALIN 1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE ACTIVITY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; METASTASIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR INVASION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOMA, SEROUS; DISEASE PROGRESSION; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TALIN;

EID: 84879352308     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1400     Document Type: Article

References (36)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
2. Mo YY: MicroRNA regulatory networks and human disease. Cell Mol Life Sci 69: 3529-3531, 2012.
3. Zamore PD and Haley B: Ribo-gnome: The big world of small RNAs. Science 309: 1519-1524, 2005. (Pubitemid 41266468)
4. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005. (Pubitemid 40839735)
5. Iorio MV, Visone R, Di Leva G, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007. (Pubitemid 47437445)
6. Olson P, Lu J, Zhang H, et al: MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 23: 2152-2165, 2009.
7. Laios A, O'Toole S, Flavin R, et al: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7: 35, 2008.
8. Rotkrua P, Akiyama Y, Hashimoto Y, Otsubo T and Yuasa Y: MiR-9 downregulates CDX2 expression in gastric cancer cells. Int J Cancer 129: 2611-2620, 2011.
9. Moore RG, Chung M, Granai CO, Gajewski W and Steinhoff MM: Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol 93: 87-91, 2004. (Pubitemid 38429553)
10. Guo R, Wu Q, Liu F and Wang Y: Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3. Oncol Rep 25: 141-146, 2011.
11. Ma L, Young J, Prabhala H, et al: MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256, 2010.
12. Chao TF, Zhang Y, Yan XQ, et al: MiR-9 regulates the expression of CBX7 in human glioma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 30: 268-274, 2008 (In Chinese).
13. Guo LM, Pu Y, Han Z, et al: MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J 276: 5537-5546, 2009.
14. Selcuklu SD, Donoghue MT, Rehmet K, et al: MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem 287: 29516-29528, 2012.
15. Malpica A, Deavers MT, Lu K, et al: Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28: 496-504, 2004. (Pubitemid 38436523)
16. Kobel M, Kalloger SE, Huntsman DG, et al: Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 29: 203-211, 2010.
17. Tan HX, Wang Q, Chen LZ, et al: MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell. Med Oncol 27: 654-660, 2010.
18. Liu N, Sun Q, Chen J, et al: MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-κB1 pathway. Oncol Rep 28: 961-968, 2012.
19. Heller G, Weinzierl M, Noll C, et al: Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res 18: 1619-1629, 2012.
20. Iorio MV and Croce CM: MicroRNA involvement in human cancer. Carcinogenesis 33: 1126-1133, 2012.
21. Lehmann U, Hasemeier B, Christgen M, et al: Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 214: 17-24, 2008.
22. Du Y, Liu Z, Gu L, et al: Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo. BMC Cancer 12: 249, 2012.
23. Lujambio A, Calin GA, Villanueva A, et al: A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105: 13556-13561, 2008.
24. Wan HY, Guo LM, Liu T, Liu M, Li X and Tang H: Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer 9: 16, 2010.
25. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
26. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
27. Vachon PH: Integrin signaling, cell survival, and anoikis: Distinctions, differences, and differentiation. J Signal Transduct 2011: 738137, 2011.
28. Desiniotis A and Kyprianou N: Significance of talin in cancer progression and metastasis. Int Rev Cell Mol Biol 289: 117-147, 2011.
29. Fong YC, Liu SC, Huang CY, et al: Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 64: 263-270, 2009.
30. Huang Y, Zhang X, Jiang W, et al: Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique. Eur J Obstet Gynecol Reprod Biol 165: 96-103, 2012.
31. Vang R, ShihleM and Kurman RJ: Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16: 267-282, 2009.
32. Critchley DR and Gingras AR: Talin at a glance. J Cell Sci 121: 1345-1347, 2008. (Pubitemid 351936298)
33. Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: Its functions and alterations in human cancer. Apoptosis 9: 667-676, 2004. (Pubitemid 40941196)
34. Hwang YP, Yun HJ, Choi JH, et al: Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol Nutr Food Res 55: 594-605, 2011.
35. Ren K, Jin H, Bian C, et al: MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway. J Biol Chem 283: 35598-35605, 2008.
36. Sakamoto S, McCann RO, Dhir R and Kyprianou N: Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res 70: 1885-1895, 2010.